Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment

Alzheimer’s Disease Neuroimaging Initiative

doi:10.3233/JAD-150804

Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment

Standard

Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment. / Alzheimer’s Disease Neuroimaging Initiative.

in: J ALZHEIMERS DIS, Jahrgang 51, Nr. 3, 2016, S. 867-73.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Alzheimer’s Disease Neuroimaging Initiative 2016, 'Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment', J ALZHEIMERS DIS, Jg. 51, Nr. 3, S. 867-73. https://doi.org/10.3233/JAD-150804

APA

Alzheimer’s Disease Neuroimaging Initiative (2016). Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment. J ALZHEIMERS DIS, 51(3), 867-73. https://doi.org/10.3233/JAD-150804

Vancouver

Alzheimer’s Disease Neuroimaging Initiative. Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment. J ALZHEIMERS DIS. 2016;51(3):867-73. https://doi.org/10.3233/JAD-150804

Bibtex

@article{c3390cdf76cd43c89c93383d4b6dbdc5,

title = "Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment",

abstract = "MRI-based hippocampus volume, a core feasible biomarker of Alzheimer's disease (AD), is not yet widely used in clinical patient care, partly due to lack of validation of software tools for hippocampal volumetry that are compatible with routine workflow. Here, we evaluate fully-automated and computationally efficient hippocampal volumetry with FSL-FIRST for prediction of AD dementia (ADD) in subjects with amnestic mild cognitive impairment (aMCI) from phase 1 of the Alzheimer's Disease Neuroimaging Initiative. Receiver operating characteristic analysis of FSL-FIRST hippocampal volume (corrected for head size and age) revealed an area under the curve of 0.79, 0.70, and 0.70 for prediction of aMCI-to-ADD conversion within 12, 24, or 36 months, respectively. Thus, FSL-FIRST provides about the same power for prediction of progression to ADD in aMCI as other volumetry methods. ",

keywords = "Aged, Aging/pathology, Alzheimer Disease/diagnostic imaging, Area Under Curve, Cognitive Dysfunction/diagnostic imaging, Databases, Factual, Disease Progression, Hippocampus/diagnostic imaging, Humans, Image Interpretation, Computer-Assisted/methods, Magnetic Resonance Imaging/methods, Neuropsychological Tests, Organ Size, Pattern Recognition, Automated/methods, Prognosis, ROC Curve, Reproducibility of Results, Risk, Sensitivity and Specificity, Time Factors",

author = "Per Suppa and Harald Hampel and Timo Kepp and Catharina Lange and Lothar Spies and Fiebach, {Jochen B} and Bruno Dubois and Ralph Buchert and {Alzheimer{\textquoteright}s Disease Neuroimaging Initiative}",

year = "2016",

doi = "10.3233/JAD-150804",

language = "English",

volume = "51",

pages = "867--73",

journal = "J ALZHEIMERS DIS",

issn = "1387-2877",

publisher = "IOS Press",

number = "3",

}

RIS

TY - JOUR

T1 - Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment

AU - Suppa, Per

AU - Hampel, Harald

AU - Kepp, Timo

AU - Lange, Catharina

AU - Spies, Lothar

AU - Fiebach, Jochen B

AU - Dubois, Bruno

AU - Buchert, Ralph

AU - Alzheimer’s Disease Neuroimaging Initiative

PY - 2016

Y1 - 2016

N2 - MRI-based hippocampus volume, a core feasible biomarker of Alzheimer's disease (AD), is not yet widely used in clinical patient care, partly due to lack of validation of software tools for hippocampal volumetry that are compatible with routine workflow. Here, we evaluate fully-automated and computationally efficient hippocampal volumetry with FSL-FIRST for prediction of AD dementia (ADD) in subjects with amnestic mild cognitive impairment (aMCI) from phase 1 of the Alzheimer's Disease Neuroimaging Initiative. Receiver operating characteristic analysis of FSL-FIRST hippocampal volume (corrected for head size and age) revealed an area under the curve of 0.79, 0.70, and 0.70 for prediction of aMCI-to-ADD conversion within 12, 24, or 36 months, respectively. Thus, FSL-FIRST provides about the same power for prediction of progression to ADD in aMCI as other volumetry methods.

AB - MRI-based hippocampus volume, a core feasible biomarker of Alzheimer's disease (AD), is not yet widely used in clinical patient care, partly due to lack of validation of software tools for hippocampal volumetry that are compatible with routine workflow. Here, we evaluate fully-automated and computationally efficient hippocampal volumetry with FSL-FIRST for prediction of AD dementia (ADD) in subjects with amnestic mild cognitive impairment (aMCI) from phase 1 of the Alzheimer's Disease Neuroimaging Initiative. Receiver operating characteristic analysis of FSL-FIRST hippocampal volume (corrected for head size and age) revealed an area under the curve of 0.79, 0.70, and 0.70 for prediction of aMCI-to-ADD conversion within 12, 24, or 36 months, respectively. Thus, FSL-FIRST provides about the same power for prediction of progression to ADD in aMCI as other volumetry methods.

KW - Aged

KW - Aging/pathology

KW - Alzheimer Disease/diagnostic imaging

KW - Area Under Curve

KW - Cognitive Dysfunction/diagnostic imaging

KW - Databases, Factual

KW - Disease Progression

KW - Hippocampus/diagnostic imaging

KW - Humans

KW - Image Interpretation, Computer-Assisted/methods

KW - Magnetic Resonance Imaging/methods

KW - Neuropsychological Tests

KW - Organ Size

KW - Pattern Recognition, Automated/methods

KW - Prognosis

KW - ROC Curve

KW - Reproducibility of Results

KW - Risk

KW - Sensitivity and Specificity

KW - Time Factors

U2 - 10.3233/JAD-150804

DO - 10.3233/JAD-150804

M3 - SCORING: Journal article

C2 - 26923010

VL - 51

SP - 867

EP - 873

JO - J ALZHEIMERS DIS

JF - J ALZHEIMERS DIS

SN - 1387-2877

IS - 3

ER -